Billiontoone, Inc. (NASDAQ:BLLN – Get Free Report) CTO David Tsao sold 20,000 shares of the company’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $98.77, for a total transaction of $1,975,400.00. Following the sale, the chief technology officer directly owned 1,000 shares of the company’s stock, valued at approximately $98,770. This trade represents a 95.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
David Tsao also recently made the following trade(s):
- On Tuesday, August 25th, David Tsao sold 10,000 shares of Billiontoone stock. The shares were sold at an average price of $100.00, for a total value of $1,000,000.00.
- On Monday, August 10th, David Tsao sold 10,000 shares of Billiontoone stock. The shares were sold at an average price of $92.86, for a total value of $928,600.00.
- On Monday, June 15th, David Tsao sold 20,000 shares of Billiontoone stock. The stock was sold at an average price of $102.27, for a total value of $2,045,400.00.
Billiontoone Stock Up 0.3%
Shares of BLLN stock traded up $0.26 during trading hours on Friday, reaching $98.77. The company had a trading volume of 406,007 shares, compared to its average volume of 543,328. The company has a market capitalization of $4.66 billion and a P/E ratio of 141.10. The company has a debt-to-equity ratio of 0.17, a quick ratio of 11.31 and a current ratio of 11.69. Billiontoone, Inc. has a twelve month low of $61.96 and a twelve month high of $150.44. The stock’s fifty day simple moving average is $112.07 and its 200 day simple moving average is $95.79.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on BLLN shares. BTIG Research decreased their target price on shares of Billiontoone from $142.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Canaccord Genuity Group began coverage on shares of Billiontoone in a research note on Wednesday, September 2nd. They set a “buy” rating and a $120.00 price target on the stock. Guggenheim assumed coverage on shares of Billiontoone in a report on Monday, June 29th. They issued a “buy” rating and a $125.00 price objective on the stock. Zacks Research cut shares of Billiontoone from a “hold” rating to a “strong sell” rating in a research report on Monday, August 31st. Finally, Wall Street Zen downgraded Billiontoone from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Billiontoone has a consensus rating of “Hold” and a consensus target price of $125.88.
Read Our Latest Research Report on BLLN
Institutional Trading of Billiontoone
A number of hedge funds and other institutional investors have recently made changes to their positions in BLLN. Adams Street Partners LLC bought a new position in Billiontoone during the 4th quarter valued at $140,063,000. Wasatch Advisors LP increased its position in shares of Billiontoone by 40.2% in the 2nd quarter. Wasatch Advisors LP now owns 518,084 shares of the company’s stock worth $62,160,000 after purchasing an additional 148,446 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in shares of Billiontoone in the 4th quarter valued at about $39,717,000. JPMorgan Chase & Co. acquired a new stake in shares of Billiontoone in the 4th quarter valued at about $32,078,000. Finally, Emerald Advisers LLC lifted its position in shares of Billiontoone by 26.8% during the first quarter. Emerald Advisers LLC now owns 239,562 shares of the company’s stock worth $18,911,000 after purchasing an additional 50,613 shares during the last quarter.
About Billiontoone
BillionToOne, Inc is a molecular diagnostics company that develops blood-based tests designed to provide genetic and health information from small amounts of biological material. The company’s technology uses its proprietary quantitative counting template approach to improve the accuracy and sensitivity of molecular testing.
The company’s primary offerings include UNITY, a portfolio of prenatal genetic tests. These services support screening for chromosomal conditions, single-gene disorders and carrier status, and are designed to help healthcare providers assess fetal and maternal genetic risks using a maternal blood sample.
See Also
- Five stocks we like better than Billiontoone
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Billiontoone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Billiontoone and related companies with MarketBeat.com's FREE daily email newsletter.
